Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Pfizer : Ardern receives Covid-19 jab to set example amid slow campaign

06/18/2021 | 02:53am EDT

Sydney, Australia, Jun 18 (EFE).- New Zealand Prime Minister Jacinda Ardern whose management against Covid-19 has been considered the best in the world, received Friday her first dose of Pfizer, amid an immunization campaign criticized for its slow deployment.

"I didn't want to be the first ... but I also wanted to be an example," Ardern told reporters after receiving her first dose of Pfizer in a city center in Auckland, the most populous city in the country.

Only 340,000 of the more than 5 million inhabitants have received both doses of the vaccines, equivalent to 7.7 percent of the population, according to the immunization schedule that began in February with workers at border posts and quarantine centers.

After vaccinating workers in the health sector and jobs at risk of contagion, health authorities are currently inoculating vulnerable people, and as of Jul. 28 they will do so with the bulk of the population, according to the age-segmented program that must conclude before the end of the year.

Explaining the slowness of the rollout, Ardern previously told Radio New Zealand that her country is one of the few that "has chosen to use Pfizer as a vaccine that will be used predominantly for the entire population."

"Not many countries are doing this. This means we have different distribution schedules," she added.

New Zealand, which has kept its international borders closed since March 2020 and has resumed normal life for months, is second last in the Organization for Cooperation and Economic Development's ranking of Covid-19 vaccination campaigns that covers 115 countries.

"It is clear that our deployment of vaccines is chaos," said Chris Bishop, spokesman for the opposition National Party on the Response to Covid-19, at the beginning of the month, adding that "it is very likely that the reopening of the border is postponed due to a delay in vaccination."

New Zealand, whose management of the pandemic has been considered the best in the world, has accumulated 2,358 Covid-19 infections since the pandemic began, including 356 cases classified as probable, and 26 deaths, as well as 23 active infections, all in quarantine centers for travelers. EFE

© 2021 EFE News Services (U.S.) Inc., source EFE Ingles

All news about PFIZER, INC.
10:43aCORONAVIRUS : Kenya has Received an Additional 410,000 Doses of AstraZeneca The ..
07:20aMODERNA : Pfizer And Moderna Ramp Up EU COVID Vaccine Prices- FT
07:19aThe new price for a pfizer shot was €19.50 against €15.50 previously, accordi..
07:18aPfizer and moderna ramp up eu covid vaccine prices- ft
07/31CORONAVIRUS- SOUTH AFRICA : SA Ramps Up COVID-19 Inoculation The department will..
07/30MODERNA : Most COVID-19 cases in Massachusetts outbreak among vaccinated, says C..
07/30Today on Wall Street: Without a care in the world
07/30Misleading With Numbers
07/30PFIZER : Israel begins administering Pfizer booster shot to over 60s 
07/30PFIZER : Israel delivers booster shots of vaccine to people over 60
More news
Financials (USD)
Sales 2021 79 237 M - -
Net income 2021 18 862 M - -
Net Debt 2021 27 050 M - -
P/E ratio 2021 12,2x
Yield 2021 3,69%
Capitalization 240 B 240 B -
EV / Sales 2021 3,37x
EV / Sales 2022 4,10x
Nbr of Employees 78 500
Free-Float 59,2%
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | PFE | US7170811035 | MarketScreener
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 24
Last Close Price 42,81 $
Average target price 43,42 $
Spread / Average Target 1,42%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Global Supply
Mikael Dolsten Chief Scientific Officer & Research President
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Aida Habtezion Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.16.30%239 637
JOHNSON & JOHNSON9.42%453 313
ROCHE HOLDING AG13.38%337 105
NOVARTIS AG0.28%225 343
NOVO NORDISK A/S35.94%212 048